Berkshire Sterile Manufacturing, Inc.

DUBLIN--( BUSINESS WIRE )--The "State of the Biopharmaceutical Industry 2024 Edition" report has been added to ResearchAndMarkets.com's offering. While the fight against COVID-19 is not in the distant past, it has been already overshadowed by a range of macroeconomic and geopolitical factors. At the same time, ongoing drug pricing and reimbursement constraints, regulatory pressures, and biotech funding instability will continue to test pharmaceutical industry in the coming years. The State of the Biopharmaceutical Industry 2024 report examines the business environment and trends that are going to shape the biopharmaceutical industry in 2024. The report highlights the most impactful emerging technologies, industry trends, regulatory trends, and microeconomic factors that are going to impact and dominate the industry throughout 2024. Post-COVID-19 recovery is met by a range of macroeconomic and geopolitical challenges. Genomics, IO drug development, personalized/precision medicine and CGTs will dominate as the most impactful trends in the biopharmaceutical industry in 2024. Among the most impactful trends, cell and gene therapies will be the key focus in 2024. Geopolitical conflicts, inflation, and drug pricing pressures will be the top hindrances for pharmaceutical sector growth. Vertical integration, patent expiry of biologics, and ESG factors are anticipated to have the greatest positive impact on the pharmaceutical industry. Big data and AI will continue to dominate as transformational forces in the healthcare sector in 2024. Across pharma value chain components, drug development and end users experience are lagging behind with innovation adoption. The biopharmaceutical industry is more optimistic about industry growth in the next 12 months as compared to 2023, but level of optimism is still below 2022 levels. A total of 44% of survey respondents expressed an optimistic or very optimistic sentiment on the biotech funding recovery in 2024. Oncology, CNS, and infectious diseases will be the dominant areas for clinical trials initiated in 2023. Oncology remains the single largest therapy area going into 2024, but metabolic disorders display the highest growth. The IRA is believed to open the door to government price negotiation across all pharmaceuticals. Key Highlights There is hope for more stability in 2024, but the road is still rocky. CGT is the trend that will continue to have the greatest impact on the pharmaceutical industry in 2024. Inflation, geopolitical conflicts, and drug pricing and reimbursement-related concerns will be the leading impediment to industry growth. Vertical integration, patent expiry of biologics, and ESG factors will have the most positive impacts on industry. AI is set to bring disruptive change in pharmaceutical industry Optimism about the pharmaceutical sector's growth prospects recovered from the lows seen in 2023. Report Scope Benchmark the impact of major themes on the biopharmaceutical industry in 2024, including: emerging technologies, regulatory trends, macroeconomic trends, industry trends. Identify themes that will have the greatest positive or negative impact in 2024. Capture opinions on these themes from industry respondents. Predict the industry's growth prospects in 2024. Key Topics Covered: Executive Summary Study Design Emerging Industry Trends Emerging Regulatory and Macroeconomic Trends Emerging Technologies Industry's Growth Prospects Watch Outs Summary of Key Findings A selection of companies mentioned in this report includes AbbVie Absci Actinium Pharmaceutical Adaptimmune Aetna Altaris Capital Partners Alvotech Amgen Aqemia Astellas Pharma AstraZeneca Bayer BenevolentAI Berkshire Sterile Manufacturing (BSM) Biocon Biologics Biogen BioNTech Biosynth Bio-Thera Solutions Boehringer Ingelheim BridgeBio Pharma Bristol Myers Squibb Catalent Celares Gmbh Celltrion Cigna's CVS Health Day One Biopharmaceutical Dr Reddy's lab Eli Lilly Exelead Express Scripts Exscientia Ferring Pharma Formycon Fresenius Kabi Fuji Pharma Genmab Geron Corp IASO Bio ImmunityBio Incyte Insilico Insud Pharma Johnson & Johnson Junshi Bio Juventas Karuna Therapeutics Lonza mAbxience Madrigal Pharmaceuticals Inc Merck & Co Metrics Contract Services Mochida Pharmaceutical Moderna Mylan Novartis Novo Nordisk Optum Amedisys Pear Therapeutics Pfizer Regeneron Roche Samsung Bioepis Sandoz Sanofi Seres Therapeutics Sharp Services Inc STgen Bio Strides Pharma Science Synaffix Syndax Pharmaceutical Teladoc Health TheraPlatform Tricida UnitedHealth Veranova Verona Pharma Plc Viatris Zhaoke Ophthalmology For more information about this report visit https://www.researchandmarkets.com/r/kj2v51 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

JERSEY CITY, N.J., Oct. 25, 2023 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on "Global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Size, Share & Trends Analysis Report By Type of Container (Sterile Cartridges, Sterile Syringes, and Sterile Vials), Type of Closure (Caps, Plungers, Seals, Stoppers, Tip Caps / Needle Shields), Material of Fabrication (Aluminum, Glass, Plastic, and Rubber)-Market Outlook And Industry Analysis 2031." Continue Reading InsightAce Analytic Pvt. Ltd According to the latest research by InsightAce Analytic, the global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market size is valued at US$ 8.42 Bn in 2022, and it is expected to reach US$ 14.23 Bn in 2031, recording a promising CAGR of 6.13% during the forecast period of 2023-2031. The primary packaging of drugs and vaccines is important in ensuring their integrity, quality and protecting them from contaminants. Hence, sterilization is essential in pharmaceutical manufacturing because it helps maintain product safety and adhere to strict quality standards. This has increased the importance of pre-sterilized/ready-to-use containers in pharmaceutical packaging. Ready-to-use vials eliminate the need for in-house sterilization processes, reducing contamination risks and production timelines. The surging demand for safe drug delivery systems has enhanced the growth of the Pre-Sterilized/Ready to Use Pharmaceutical packaging market. Recent advances in packaging materials and technologies have resulted in innovative solutions offering high drug compatibility, stability, and barrier properties. The advantages offered by empty sterile vials and syringes, and their increasing demand in the healthcare sector, specifically after the COVID-19 pandemic, have prompted manufacturers to implement advancements that are likely to propel the market growth during the forecast period. Request for Sample Pages: Some of the prominent players in the Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market are: ABB Afton Scientific ALK Life Science Solutions Allergy Laboratories AptarGroup Aseptic Technologies Becton Dickinson Berkshire Sterile Manufacturing Bharat Rubber Works BioPharma Solutions Bormioli Pharma Catalent Centor COLANAR Corning Credence MedSystems Daikyo Seiko Dara Pharmaceutical Packaging Datwyler Group DENSO Disposable-Lab (Acquired by Amatsigroup) DWK Life Sciences EMA Pharmaceuticals Amatsigroup (Acquired by Eurofins CDMO) FANUC America GCL Pharma (Acquired by Bormioli Pharma) Gerresheimer Huayi Isotopes Company IMA ISOLAB Jiangsu Hualan New Pharmaceutical Material Kawasaki Heavy Industries Klenzaids Contamination Controls KUKA Marchesini Group MedCision MedicoPack Merck Momentive Technologies Muller + Muller (Acquired by DWK Life Sciences) Nelson Labs Nemera Ningbo Zhengli Pharmaceutical Packaging Nipro OMRON Industrial Automation Origin Pharma Packaging Ott (Acquired by Datwyler Group) Pall Pfeiffer Vacuum Pfizer Philabundance Prince Sterilization Services Qingdao Huaren Medical Product Radpharm Scientific Retractable Technologies Sagar Rubber Samsung Medical Rubber Sartorius SCHOTT Seiko Epson SGD Pharma SiO2 Materials Science Sonata Rubber Staubli Steriline Sterisets International Stevanato Group SureCare SVM Automatik Swissfillon Syntegon Tekpak Terumo Toxikon Europe (Acquired by Sterigenics International) Transcoject Triveni Polymers (Acquired by Gerresheimer) Universal Medicap Universal Robots United Pharmacy Partners (UPPI) Vaccines Manufacturing and Innovation Centre Vanrx Pharmasystems Vetter Pharma VIGHNESH Rubbers Watson-Marlow Fluid Technology Group West Pharmaceutical Services YangZhong Wealth Metal Yaskawa Electric Ypsomed Curious about this latest version of the report? Enquiry Before Buying: Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Report Scope Market Dynamics: Drivers: The main factors responsible for driving the Pre-Sterilized/Ready to Use Pharmaceutical packaging market are increasing preference towards patient safety and rising importance for sterility and integrity of pharmaceutical products. In addition, strict regulatory guidelines set by regulatory agencies such as the FDA and EMA play an essential role in booming the demand for pre-sterilized pharmaceutical packaging. Moreover, the complex manufacturing of advanced therapies such as cell and gene therapies led to a surge in the need for suitable containers for ATMP aseptic filling & finishing. The addition of RTU (ready-to-use) packaging into the pharmaceutical industry ensures that the product is quickly available through the optimized supply chain. Further, the high demand for COVID-19 vaccines has boosted market growth, especially for sterile vials. Regional Trends: North America captured the highest revenue share of the Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market in 2022 and is expected to continue its growth during the forecast period 2023-2031. This growth can be attributed to the increasing demand for pharmaceutical products, well-developed healthcare infrastructure, and rising government efforts and investments in developing pharmaceutical facilities. Besides, the Asia Pacific region is anticipated to grow faster in the next few years. Key developments in the market: In June 2022, Schott invested multi-Bn euros to increase sterile RTU vials production at its facility in Pennsylvania, US. In March 2022, Stevanato expanded its vial manufacturing operations to meet the need for vaccines during the pandemic under a contract with the Biomedical Advanced Research and Development Authority (BARDA). The company has invested in expanding the production capacity for both standard RTU vials and EZ fill RTU vials. In March 2022, SGD Pharma introduced a 100 ml ready-to-use sterile glass vial, catering to the demand for small and large sterile vials. Market Segments Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Container Sterile Cartridges Sterile Syringes Sterile Vials Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Closure Caps Plungers Seals Stoppers Tip Caps / Needle Shields Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Material of Fabrication Aluminum Glass Rubber Plastic Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Region North America Europe Asia Pacific Latin America Middle East & Africa North America Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 U.S. Canada Europe Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 Germany France Italy Spain Russia Rest of Europe Asia Pacific Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 India China Japan South Korea Australia & New Zealand Latin America Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 Brazil Mexico Rest of Latin America Middle East & Africa Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 GCC Countries South Africa Rest of Middle East & Africa Obtain Report Customization Details @ Why should buy this report: To receive a comprehensive analysis of the prospects for the global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market To receive an industry overview and future trends in the global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market To analyze the Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market drivers and challenges To get information on the Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market size value (US$ Mn) forecast till 2031 Major Investments, Mergers & Acquisitions in the global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market industry Other Related Reports Published by InsightAce Analytic: Pharmaceutical Packaging Market Research Report 2023 Sustainable Pharmaceutical Packaging Market Research Report 2023 Pharmaceutical Plastic Bottles Market Research Report 2023 About Us: InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner. Contact Us: InsightAce Analytic Pvt. Ltd. Tel.: +1 551 226 6109 Email: [email protected] Site Visit: Follow Us on LinkedIn @ bit.ly/2tBXsgS Follow Us On Facebook @ bit.ly/2H9jnDZ Logo - SOURCE InsightAce Analytic Pvt. Ltd

Berkshire Sterile Manufacturing is a fill finish contract development and manufacturing organisation with a focus on clinical and commercial sterile injectable products The clinical packaging site of Sharp in Bethlehem, Pennsylvania. (Credit: GlobeNewswire/Berkshire Sterile Manufacturing) Sharp, a clinical trial supply services and pharmaceutical packaging provider, has acquired Massachusetts, US-based Berkshire Sterile Manufacturing (BSM) for an undisclosed sum. Berkshire Sterile Manufacturing is a fill finish contract development and manufacturing organisation (CDMO) with a focus on clinical and commercial sterile injectable products. The deal is expected to enable Sharp to provide a range of fully integrated small-to-medium scale sterile injectable services to the biopharmaceutical sector. It also expands the company’s network of capabilities in the US. The acquisition follows the 2020 deal under which Sharp purchased a minority 25% ownership in Berkshire Sterile Manufacturing. Their partnership started in 2018 when the pharmaceutical packaging firm signed a preferred partner agreement with the latter. According to the CDMO, the current clinical supply, packaging, and distribution solutions of Sharp will complement Berkshire Sterile Manufacturing’s sterile manufacturing expertise. Together, the companies will provide integrated CDMO services to different biopharmaceutical customers globally. Sharp and Berkshire Sterile Manufacturing will offer services for sterile drug product manufacturing, clinical trials, commercial packaging, and distribution. Sharp president and CEO Kevin Orfan said: “With sterile injectables a huge part of addressing this unmet medical need, the acquisition of BSM allows Sharp to provide a fully integrated solution for our biopharma clients that is a natural extension of our existing injectables and clinical packaging expertise. “This acquisition, which builds on the existing partnership between our two companies, will greatly benefit our clients, creating an efficient manufacturing and distribution service for biotech companies developing sterile injectable products across the world.” Established in 2014, Berkshire Sterile Manufacturing started with small-scale clinical and commercial drug product manufacturing with sterility assurance and quality. The company now offers fill-finish services that include lyophilisation capabilities and dedicated isolator-based sterile filling of vials, syringes, and cartridges. Berkshire Sterile Manufacturing’s 228 employees will join the Sharp family and continue to work from its facility in Lee, Massachusetts. Berkshire Sterile Manufacturing co-founder and CEO Shawn Kinney said: “This is an exciting development for everyone at BSM and for our clients, who will benefit from a seamless downstream packaging, labelling, storage, and distribution service through Sharp’s network of facilities and expertise.”